Developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy

开发定量超声乳腺扫描仪来识别乳腺癌对化疗的早期反应

• 批准号: 10504175
• 负责人: Gregory Jan Czarnota
• 金额: $ 60.38万
• 依托单位: UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-18 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10504175
• 关键词: 3-Dimensional; Address; Anatomy; Breast Cancer Patient; Breast Cancer therapy; Clinical; Clinical Data; Contrast Media; Data; Detection; Devices; Disease-Free Survival; Early identification; Feedback; Frequencies; Hand; Health Sciences; Human; Image; In complete remission; Institution; Ionizing radiation; Knowledge; Magnetic Resonance Imaging; Malignant Neoplasms; Mammary Ultrasonography; Mammography; Marriage; Measures; Monitor; Neoadjuvant Therapy; Operative Surgical Procedures; Outcome; Pathologic; Patient-Focused Outcomes; Patients; Performance; Physical assessment; Process; Prognosis; Radiation; Resolution; Savings; Scanning; Signal Transduction; Speed; Techniques; Technology; Testing; Time; Tissues; Translating; attenuation; base; breast imaging; breast scanner; cancer therapy; chemotherapy; cohort; cost; data acquisition; improved; individual patient; malignant breast neoplasm; patient response; personalized medicine; quantitative imaging; quantitative ultrasound; response; sound; success; tomography; transmission process; treatment response; tumor; ultrasound

PROJECT SUMMARY In this proposal, we will develop new images modes on the QT Ultrasound® tomographic breast scanner and demonstrate that the scanner with the new image modes can accurately identify the response of breast cancer patients to chemotherapy. A poorly met clinical need in breast cancer therapy is providing inexpensive and accurate ways to identify patient responses to chemotherapy early during the course of therapy. For many breast cancers, lack of patient response to initial therapy is predictive of poor outcome, whereas pathological complete response strongly correlates with extended survival. Conventional clinical surrogates of response based on anatomical information such as physical assessments, mammography and standard clinical ultrasound provide poor early assessments of treatment response. We demonstrated that quantitative analysis of ultrasound backscatter (QUSB) using conventional hand-held clinical scanners can provide promising metrics of response of breast cancer to neoadjuvant chemotherapy (NAC/AC) within one week of therapy initiation. These QUSB results would benefit greatly from improved volumetric accuracy that conventional scanning platforms do not support, such as transmission and attenuation losses in the signals. We propose to solve these issues by integrating QUSB with the newly available QT Ultrasound® breast scanner. This FDA cleared and marketed scanner delivers 3D quantitative images of the breast including sound speed, (SOS) reflectivity (R) and attenuation (A) values. The QT Ultrasound® breast scanner corrects refractive and interface attenuation losses. It also provides compounding of multiple angles of view that will further improve QUSB variance. The scanner’s parameters of SOS, R, A, and mm3 volume measuring accuracy provide supplementary quantitative features likely to contribute robustness to early identification of response. We believe that the QUSB+QT Ultrasound® breast scanner can identify response at a level better than MRI. Even if response identification is only comparable, QUSB+QT Ultrasound® savings in costs, ease of use, noninvasive native contrast, and patient acceptance would markedly simplify management of breast cancer therapy and deliver considerable practical advantage and increased accuracy. Therefore, our scientific premise is that QUSB integrated on the QT Ultrasound® breast scanner will provide improved identification of early response of breast cancer patients to NAC. Our preliminary data demonstrate that QUSB techniques can identify nonresponders and predict patient outcomes. Our preliminary results also demonstrate that QUSB techniques integrate with the QT Ultrasound® platform and benefit from improved QUSB bias and variance. Therefore, the proposal consists of three aims. The first specific aim is to implement, test and validate QUSB techniques on the latest QT Ultrasound® breast scanner for clinical data acquisition. The second specific aim is to quantify the capacity of QUSB+QT Ultrasound® quantitative data to identify nonresponders. The final specific aim is to quantify the capacity of QUSB+QT Ultrasound® quantitative data to predict patient outcomes.

项目概要 在此提案中，我们将在 QT Ultrasound® 乳腺断层扫描仪上开发新的图像模式， 证明具有新图像模式的扫描仪可以准确识别乳腺癌的反应 乳腺癌治疗的临床需求尚未得到满足，而化疗药物价格低廉且价格低廉。 对于许多乳腺癌患者来说，这是在治疗过程早期确定患者对化疗反应的准确方法。 在癌症中，患者对初始治疗缺乏反应预示着结果不佳，而病理完全 反应与基于反应的传统临床替代指标密切相关。 身体评估、乳房X线摄影和标准临床超声等解剖信息提供 我们证明了超声定量分析对治疗反应的早期评估不佳。 使用传统手持式临床扫描仪的反向散射（QUSB）可以提供有希望的响应指标 治疗开始后一周内进行乳腺癌新辅助化疗 (NAC/AC)。 结果将大大受益于传统扫描平台无法做到的体积精度的提高 支持，例如信号的传输和衰减损耗。 我们建议通过将 QUSB 与新推出的 QT Ultrasound® 乳房集成来解决这些问题 这款经 FDA 批准并上市的扫描仪可提供包括声音在内的乳房 3D 定量图像。 速度、(SOS) 反射率 (R) 和衰减 (A) 值 QT Ultrasound® 乳房扫描仪可校正屈光。 它还提供了多个视角的复合，这将进一步改善。 扫描仪的 SOS、R、A 和 mm3 体积测量精度参数提供了 QUSB 方差。 补充定量特征可能有助于早期识别反应的稳健性。 我们相信 QUSB+QT 超声乳腺扫描仪可以比 MRI 更好地识别反应。 即使响应识别仅具有可比性，QUSB+QT Ultrasound® 也可节省成本、易于使用、 无创天然造影剂和患者接受度将显着简化乳腺癌的治疗 疗法并提供相当大的实际优势和更高的准确性，因此，我们的科学前提。 QUSB 集成在 QT Ultrasound® 乳房扫描仪上将提供更好的早期诊断 我们的初步数据表明 QUSB 技术可以识别乳腺癌患者对 NAC 的反应。 我们的初步结果也表明 QUSB 技术。 与 QT Ultrasound® 平台集成并受益于改进的 QUSB 偏差和方差。 该提案包含三个目标。第一个具体目标是在 QUSB 上实施、测试和验证 QUSB 技术。 用于临床数据采集的最新 QT 超声波® 乳房扫描仪第二个具体目标是量化。 QUSB+QT Ultrasound® 定量数据的能力来识别无反应者的最终具体目标是。 量化 QUSB+QT Ultrasound® 定量数据预测患者结果的能力。